Anti-CD19-Anti-CD3 IgG format Bispecific Antibody

Only %1 left

Catalog #

101076

As low as $390 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Anti-CD19-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CD19-CHO cells (BPS Bioscience #79561-H) that overexpress CD19.

●

Product Data Gallery

4-20% SDS-Page Coomassie Staining

Activation of NFAT-Jurkat Reporter cells by Anti-CD19- Anti-CD3 IgG in the presence of CD19-CHO cells

Product Info

Storage and Usage

Citations

Species

Human

Construct

Anti-CD19-Heavy and Light Chains, Anti CD3-Heavy and Light Chains

Isotype

IgG1

Host Species/Expression System

Co-expressed in HEK293

Purity

≥90%

Purification

Protein A affinity purification of the IgG-tag protein from HEK293 cells.

Format

Aqueous buffer solution

Formulation

8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol

Heavy Chain: 50 kDa; Light Chain: 24 kDa

Storage/Stability

At least 12 months at -80°C.

Assay Conditions

Experimental design and assay protocol for measuring anti CD19-anti CD3 functional activity using NFAT-luc reporter Jurkat cell line:

Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti-CD19 x anti-CD3 bispecific antibody in the presence of CD19-CHO cells (BPS Bioscience #79561-H) or CHO cells (ATCC #CCL-61™).
1. Seed CHO and CD19-CHO cells at 30,000 cells/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate.
2. Seed Jurkat cells at 30,000 cells/well.
3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CD19 on CD19-CHO cells.
4. After 16 hours the luciferase activity is measured using ONE-Step™ luciferase assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.

Applications

This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-CD19-anti-CD3 IgG format bispecific antibody can be used for studying CD19+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as NFAT-luc-Jurkat cells (BPS Bioscience #60621).

Shipping Temperature

-80°C

Warnings

Avoid freeze/thaw cycles

Scientific Category

CAR-T

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Anti-CD19-Anti-CD3 IgG format Bispecific Antibody

PRODUCTS

SERVICES

RESOURCES

COMPANY